ABC | Volume 112, Nº5, May 2019

Short Editorial Guimarães & Caixeta Brazil: two realities for the treatment of one disease Arq Bras Cardiol. 2019; 112(5):571-572 1. Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Caré D, et al. et al. Sirolimus-eluting versus uncoated stents in acutemyocardial infarction. Ne Engl J Med. 2006;2006;355(11):1093–104. 2. Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M, et al.et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J. 2007;28(22):2706–13. 3. Baber U, Mehran R, Sharma SK, Brar S, Yu Jm Suh JW, et al. Impact of the everolimus-elutingstentonstentthrombosis:ameta-analysisof13randomized trials. J AmColl Cardiol. 2011;58J. J AmColl Cardiol. 2011;58(15):1569–77. 4. Valgimigli M, Sabaté M, Kaiser C, Brugalet al. Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis. BMJ. 2014;349:g6427. 5. Sabaté M, Brugaletta S, Cequier A, Mainar V, et al. Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial. Lancet 2016;387(10016):357–66. 6. Schur N, Brugaletta S, Cequier A, Inigues AF Cost-effectiveness of everolimus-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: An analysis from the EXAMINATION randomized controlled trial. PLoS ONE 2018;13(8):e0201985. 7. Neumann FJ, Sousa-UvaM, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS guidelines onmyocardial revascularization. Scientific Document Group. Eur Heart J. 2019;40(2):87-165. 8. Tillin T, Hughes AD, Mayet J, Whincup P, Sattar N, Foroughi NG, et al. The Relationship Between Metabolic Risk Factors and Incident Cardiovascular Disease in Europeans, South Asians, and African Caribbeans: SABRE (Southall and Brent Revisited)—A Prospective Population-Based Study. J Am Coll Cardiol. 2013;61(17):1777–86. 9. O’Donoghue ML, Vaidya A, Afsal R, Alfredsson J, BodenWE, Braunwald E, et al. An Invasive or Conservative Strategy in PatientsWithDiabetes Mellitus andNon–ST-SegmentElevationAcuteCoronarySyndromes:ACollaborative Meta-Analysis of Randomized Trials. J AmColl Cardiol.2012;60(2):106–11. 10. Patti G, Pasceri V, Melfi R, Goffredo G, Chello M, D’Ambrosio A, et al.et al. Impaired flow-mediateddilationandriskofrestenosis inpatientsundergoing coronary stent implantation. Circulation. 2005;111(1):70–5. 11. Di Sciascio G, Patti G, Nasso G, Manzoli A, D’Ambrosio A, Abbate A. Early and long-term results of stenting of diffuse coronary artery disease. Am J Cardiol. 2000;86(11):1166–70. 12. Patti G, Nusca A, Di Sciascio G. Meta-analysis comparison (nine trials) of outcomes with drug-eluting stents versus bare metal stents in patients with diabetes mellitus. Am J Cardiol. 2008;102(10):1328–34. 13. Oliveira JC, Oliveira LCS, Oliveira JC, Barretto IDC, Almeida -Santos MA, Lima TCR, et al. Disparities In The Use Of Drug-eluting Stents For Diabetic Patients With ST-elevation Acute Myocardial Infarction Assisted In the Public versus Private Network - VICTIM Register. Arq Bras Cardiol. 2019; 112(5):564-570 14. Bangalore S, Gupta N, Guo Y, Feit F. Trend in the use of drug eluting stents in the United States: insight from over 8.1 million coronary interventions. Int J Cardiol. 2014;175(1):108–19. 15. Feres F, Costa RA, Siqueira D, Costa JR Jr, Chamié D, Staico R, et al. Diretriz da Sociedade Brasileira de Cardiologia e da Socidade Brasileira de Hemodinâmica e Cardiologia Intervencionista sobre Intervenção Coronária Percutânea. Arq Bras Cardiol. 2017;109(1 Suppl 1):1-81. References This is an open-access article distributed under the terms of the Creative Commons Attribution License 572